Introduction
Materials and methods
Patients
General data collection
PET/CT acquisition and analysis
Pathological analysis
Statistical analysis
Results
General characteristics
Characteristics | Model construction (N = 224) | Model validation (N = 100) | Value | p value |
---|---|---|---|---|
Age | 63.48 ± 9.57 | 63.33 ± 9.54 | − 0.128a | 0.898 |
Gender | 0.692b | 0.406 | ||
Male | 137 | 66 | ||
Female | 87 | 34 | ||
Smoking history | 0.481b | 0.488 | ||
No | 128 | 53 | ||
Yes | 96 | 47 | ||
SUVmax of mediastinal lymph node | 1.87 (1.41, 3.29) | 2.03 (1.41, 3.76) | 11,625.00d | 0.585 |
Primary-tumor SUVmax | 7.13 (3.05, 11.28)c | 7.46 (2.78, 11.91) | 11,572.50d | 0.632 |
Primary-tumor SUVpeak | 4.48 (2.11, 7.33)c | 5.14 (2.00, 8.31) | 11,546.00d | 0.657 |
Primary-tumor SUVmean | 4.20 (1.78, 6.82)c | 4.35 (1.57, 7.15) | 11,528.00d | 0.647 |
Primary-tumor MTV | 16.51 (9.14, 35.75)c | 15.73 (9.14, 37.65) | 11,164.50d | 0.964 |
Primary-tumor TLG | 53.99 (19.15, 228.81)c | 57.43 (19.65, 244.25) | 11,313.00d | 0.885 |
Primary tumor size (mm) | 28.00 (20.00, 40.00)c | 27.50 (20.00, 38.00) | 11,350.00d | 0.847 |
CEA | 3.24 (1.95, 5.63)c | 3.07 (1.98, 5.12) | 10,935.00d | 0.734 |
CYFRA21-1 | 2.83 (2.10, 4.14)c | 2.66 (2.07, 3.96) | 10,731.50d | 0.547 |
CA19-9 | 11.22 (8.21, 17.30)c | 10.47 (7.26, 17.26) | 10,465.00d | 0.345 |
SCC | 0.93 (0.70, 1.40)c | 1.00 (0.73, 1.40) | 11,502.50d | 0.697 |
NSE | 13.05 (11.31, 15.63)c | 12.89 (10.79, 15.60) | 10,691.50d | 0.514 |
TPA | 87.56 (63.19, 134.98)c | 82.26 (63.15, 129.53) | 10,948.50d | 0.747 |
proGRP | 43.55 (34.30, 54.16)c | 44.87 (35.64, 55.24) | 11,837.50d | 0.413 |
EGFR mutation | 0.589b | 0.443 | ||
No | 166 | 70 | ||
Yes | 58 | 30 | ||
ALK rearrangement | 0.238b | 0.626 | ||
No | 205 | 95 | ||
Yes | 14 | 5 |
Analysis of the correlation of SUV-derived parameters and clinical characteristics with metastasis in mediastinal lymph nodes
Variable | Mediastinal lymph node metastasis | Total | Valuea | p value | |
---|---|---|---|---|---|
No | Yes | ||||
SUVmax of mediastinal lymph node | 36.378 | < 0.001 | |||
< 2.49 | 132 (88.0%) | 18 (12.0%) | 150 (67%) | ||
≥ 2.49 | 38 (51.4%) | 36 (48.6%) | 74 (33%) | ||
Primary-tumor SUVmax | 16.525 | < 0.001 | |||
< 4.11 | 70 (92.1%) | 6 (7.9%) | 76 (33.9%) | ||
≥ 4.11 | 100 (67.6%) | 48 (32.4%) | 148 (66.1%) | ||
Primary-tumor SUVpeak | 18.187 | < 0.001 | |||
< 2.92 | 73 (92.4%) | 6 (7.6%) | 79 (35.3%) | ||
≥ 2.92 | 97 (69.9%) | 48 (33.1%) | 145 (64.7%) | ||
Primary-tumor SUVmean | 14.430 | < 0.001 | |||
< 2.39 | 66 (91.7%) | 6 (8.3%) | 72 (32.1%) | ||
≥ 2.39 | 104 (68.4%) | 48 (31.6%) | 152 (67.9%) | ||
Primary-tumor MTV (cm3) | 7.066 | 0.008 | |||
< 30.88 | 132 (80.5%) | 32 (19.5%) | 164 (73.2%) | ||
≥ 30.88 | 38 (63.3%) | 22 (36.7%) | 60 (26.8%)) | ||
Primary-tumor TLG | 10.243 | 0.001 | |||
< 83.53 | 111 (83.5%) | 22 (16.5%) | 133 (59.4%) | ||
≥ 83.53 | 59 (64.8%) | 32 (35.2%) | 91 (40.6%) | ||
Primary solid tumor maximum diameter (mm) | 10.243 | 0.001 | |||
< 32.50 | 111 (83.5%) | 22 (16.5%) | 133 (59.4%) | ||
≥ 32.50 | 59 (64.8%) | 32 (35.2%) | 91 (40.6%) | ||
Degree of primary-tumor solidity | 17.705 | < 0.001 | |||
Partial solid | 76 (91.6%) | 6 (8.4%) | 83 (37.1%) | ||
Solid | 94 (66.7%) | 47 (33.3%) | 141 (62.9%) | ||
CEA (ng/ml) | 15.043 | < 0.001 | |||
< 3.94 | 119 (84.4%) | 22 (15.6%) | 141 (62.9%) | ||
≥ 3.94 | 51 (61.4%) | 32 (38.6%) | 83 (37.1%) | ||
CYFRA21-1 (ng/ml) | 5.16 | 0.023 | |||
< 2.10 | 48 (87.3%) | 7 (12.7%) | 55 (24.6%) | ||
≥ 2.10 | 122 (72.2%) | 47 (27.8%) | 169 (75.4%) | ||
CA19-9 (U/ml) | 6.065 | 0.014 | |||
< 16.6 | 130 (80.2%) | 32 (19.8%) | 162 (72.3%) | ||
≥ 16.6 | 40 (64.5%) | 22 (35.5%) | 62 (27.7%) | ||
SCC (ng/ml) | 4.199 a | 0.04 | |||
< 1.15 | 103 (71.5%) | 41 (28.5%) | 144 (64.3%) | ||
≥ 1.15 | 67 (83.7%) | 13 (16.3%) | 80 (35.7%) | ||
NSE (ng/ml) | 4.552 | 0.033 | |||
< 14.66 | 121 (80.1%) | 30 (19.9%) | 151 (67.4%) | ||
≥ 14.66 | 49 (67.1%) | 24 (32.9%) | 73 (32.6%) |
Predictive factor analysis for metastasis in mediastinal lymph nodes
Characteristics | Univariate analysis OR (95% CI) | p value | Multivariate regression OR (95% CI) | p value |
---|---|---|---|---|
SUVmax of mediastinal lymph node | ||||
< 2.49 | Reference | Reference | ||
≥ 2.49 | 6.947 (3.551–13.591) | < 0.001 | 7.215 (3.326–15.649) | < 0.001 |
Primary-tumor SUVmax | ||||
< 4.11 | Reference | |||
≥ 4.11 | 5.600 (2.272–13.801) | < 0.001 | ||
Primary-tumor SUVpeak | ||||
< 2.92 | Reference | Reference | ||
≥ 2.92 | 6.021 (2.444–14.829) | < 0.001 | 5.717 (2.094–15.605) | 0.001 |
Primary-tumor SUVmean | ||||
< 2.39 | Reference | |||
≥ 2.39 | 5.077 (2.058–12.525) | < 0.001 | ||
Primary-tumor MTV (cm3) | ||||
< 30.88 | Reference | |||
≥ 30.88 | 2.388 (1.244–4.583) | 0.009 b | ||
Primary-tumor TLG | ||||
< 83.53 | Reference | |||
≥ 83.53 | 2.737 (1.460–5.128) | < 0.002 | ||
Degree of primary-tumor solidity | ||||
Partial solid | Reference | |||
solid | 5.429 (2.321–12.697) | < 0.001 | ||
CEA (ng/ml) | ||||
< 3.94 | Reference | Reference | ||
≥ 3.94 | 3.394 (1.800–6.400) | < 0.001 | 2.467 (1.182–5.149) | 0.016 |
CYFRA21-1 (ng/ml) | ||||
< 2.10 | Reference | |||
≥ 2.10 | 2.642 (1.116–6.252) | 0.027 | ||
CA19-9 (U/ml) | ||||
< 16.6 | Reference | |||
≥ 16.6 | 2.234 (1.168–4.273) | 0.015 | ||
SCC (ng/ml) | ||||
< 16.6 | 2.052 (1.023–4.113) | 0.043 | 4.795 (2.019–11.388) | < 0.001 |
≥ 16.6 | Reference | Reference | ||
NSE (ng/ml) | ||||
< 14.66 | Reference | |||
≥ 14.66 | 1.976 (1.051–3.713) | 0.034 |